Treatment system

Abstract

To provide a treatment system which allows a treatment while confirming a breakage level of a tumor cell by light irradiation, and which can improve a treatment effect.SOLUTION: A treatment system 10 which applies an excitation light onto a photosensitive substance aggregates to a tumor cell, includes: an optical device 20 having an optical fiber 27 which can propagate the light between a base end part and a tip end part, and having an irradiation part 25 which can externally apply the light at the tip end part and a detection part 26 which can detect the external light; and an analysis device 40 connected to the base end part of the optical device 20 and analyzing the light detected by the detection part 26. The analysis device 40 calculates an intensity of fluorescent light received from the detection part 26. When the intensity of the fluorescent light is equal to or less than a threshold value, a threshold value reaching signal is output that shows that the intensity is equal to or less than the threshold value.SELECTED DRAWING: Figure 2

Description

Technical Field

[0001] The present invention relates to a treatment device for destroying tumor cells.

Background Art

[0002] In the treatment of breast cancer patients, breast-conserving therapy has great advantages in terms of improving the patient's quality of life. On the other hand, the current local recurrence rate after breast-conserving treatment is 10 - 20%. Therefore, the satisfaction of local treatment in breast-conserving therapy is still not high.

[0003] In local cancer treatment, a treatment method using a photoreactive substance is known as a method for destroying target cells such as tumor cells. Among them, a treatment method using an antibody-photosensitive substance (hydrophilic phthalocyanine) can specifically destroy only target cells without destroying non-target cells such as normal cells by irradiating the antibody-photosensitive substance accumulated in the tumor with excitation light (for example, near-infrared light). Therefore, this treatment method is expected to obtain a high treatment effect while minimizing side effects. Furthermore, as a treatment effect, an immune reaction through fragments of destroyed cells is induced, and a treatment effect by the body's own immune function is also expected. If such local treatment using a photoreactive substance can be applied to breast cancer patients, it is expected to obtain a high treatment effect while preserving the breast.

[0004] Patent Document 1 describes a device that can be inserted into a lactiferous duct to burn a diseased part. This device destroys not only the diseased part but also normal cells, so the burden on the living body is large.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0006] In order to obtain a high therapeutic effect of a photosensitive substance, it is necessary to surely irradiate the photosensitive substance accumulated in a tumor with excitation light. However, since the intensity of light rapidly attenuates as the distance of the transmitting tissue increases, it is very difficult to irradiate a tumor in the body from the body surface non-invasively with light of sufficient intensity. Therefore, a means for surely irradiating light to a tumor in the body while suppressing invasiveness as much as possible is required. Further, in order to maximize the therapeutic effect, it is required that the reaction of the photosensitive substance accumulated in the tumor by the excitation light can be measured during treatment. If the destruction of cancer cells by the light reaction can be measured during treatment, it becomes possible to optimally set the irradiation time and improve the therapeutic effect.

[0007] The present invention has been made to solve the above-described problems, and an object thereof is to provide a treatment system capable of treating while confirming the degree of destruction of tumor cells by light irradiation and improving the therapeutic effect.

Means for Solving the Problems

[0008] A treatment system according to the present invention that achieves the above object is a treatment system that irradiates a photosensitive substance accumulated in tumor cells with excitation light, and includes an optical fiber capable of propagating light between a base end portion and a tip end portion, and a light device including an irradiation portion capable of irradiating light to the outside at the tip end portion and a detection portion capable of detecting external light, and an analyzer connected to the base end portion of the light device and receiving and analyzing the light detected by the detection portion, wherein the analyzer calculates the intensity of fluorescence received from the detection portion and outputs a threshold arrival signal indicating that the intensity of the fluorescence has become equal to or less than a threshold value when the intensity of the fluorescence becomes equal to or less than the threshold value.

Effects of the Invention

[0009] The treatment system configured as described above arranges the irradiation unit and the detection unit of the optical device at a position close to the tumor cells, so that the photosensitive substance accumulated in the tumor cells can be effectively irradiated with the excitation light, and the fluorescence emitted by the photosensitive substance accumulated in the tumor cells can be effectively detected. Therefore, the treatment system can perform treatment while confirming the degree of destruction of tumor cells by irradiating the excitation light by detecting fluorescence, and can improve the treatment effect.

[0010] The treatment system has an analyzer connected to the base end of the optical device and receiving and analyzing the light detected by the detection unit. The analyzer calculates the intensity of the fluorescence received from the detection unit, and when the intensity of the fluorescence becomes equal to or less than a threshold value, it may output a threshold arrival signal indicating that the intensity has become equal to or less than the threshold value. Thereby, the treatment system can notify the operator that the intensity of the fluorescence has become equal to or less than the threshold value, or stop the irradiation of the excitation light.

[0011] The distal end of the optical device has an expansion part that can expand and contract in the radial direction, and the irradiation unit and the detection unit may be arranged in the expansion part. Thereby, by expanding the expansion part in the lactiferous duct, the irradiation unit and the detection unit can be arranged near the inner wall of the lactiferous duct. For this reason, the influence of the body fluid in the lactiferous duct that hinders the reach of light can be reduced, and the photosensitive substance accumulated in the tumor cells can be effectively irradiated with the excitation light from the irradiation unit, and the fluorescence emitted by the photosensitive substance accumulated in the tumor cells can be effectively detected.

[0012] In the treatment system, the photosensitive substance may include an antibody-photosensitive substance complex in which the photosensitive substance is bound to an antibody that accumulates in tumor cells. Thereby, since the accumulation property of the photosensitive substance in tumor cells is improved by the antibody bound to the photosensitive substance, tumor cells can be more reliably destroyed.

[0013] Another aspect of the treatment system according to the present invention for achieving the above object is a treatment system that irradiates excitation light to a photosensitive substance accumulated in tumor cells, comprising an optical fiber capable of propagating light between a proximal end portion and a distal end portion, an optical device provided with an irradiation unit capable of irradiating light to the outside at the distal end portion and a detection unit capable of detecting external light, and an analyzer connected to the proximal end portion of the optical device for receiving and analyzing the light detected by the detection unit, wherein the analyzer calculates the intensity of fluorescence received from the detection unit in real time and causes the calculated intensity of fluorescence to be displayed on a display panel of a display device in real time.

Brief Description of the Drawings

[0014]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Embodiments for Carrying Out the Invention

[0015] Hereinafter, embodiments of the present invention will be described with reference to the drawings. Note that the dimensions in the drawings may be exaggerated for convenience of explanation and may be different from the actual dimensions. Also, in this specification and the drawings, components having substantially the same functional configuration are denoted by the same reference numerals, and redundant explanations are omitted. In this specification, the side inserted into the living body lumen of the device is referred to as the "tip side", and the operating side is referred to as the "base end side".

[0016] <First Embodiment>

[0017] The treatment system 10 according to the first embodiment is used for photodynamic immunotherapy that destroys target cells by irradiating a photosensitive substance accumulated on the cell membrane of the target cells with near-infrared light. The target cells are tumor cells such as cancer cells. In this treatment method, an antibody-photosensitive substance in which an antibody that specifically accumulates only on a specific antigen on the surface of tumor cells and a photosensitive substance paired with the antibody are combined is used as a drug. The antibody is not particularly limited, and examples thereof include panitumumab, trastuzumab, HuJ591, pertuzumab, lapatinib, palbociclib, olaparib, and the like. The photosensitive substance is, for example, a hydrophilic phthalocyanine (IR700) that reacts to near-infrared light with a wavelength of about 700 nm, or a hydrophilic phthalocyanine (IR800) that reacts to near-infrared light with a wavelength of about 789 to 794 nm, but is not limited thereto. When IR700 receives near-infrared light with a wavelength of about 660 to 740 nm, the ligand of the functional group that ensures water solubility is cleaved, and a structural change occurs from water solubility to hydrophobicity. Due to this structural change, membrane proteins are extracted, holes are opened in the cell membrane, and water enters the cell, so that cancer cells can be ruptured and destroyed. In addition, IR700 is excited by receiving near-infrared light and emits fluorescence with a wavelength different from the excitation wavelength. For example, when IR700 is excited by receiving near-infrared light with a wavelength of 689 nm, it emits fluorescence with a wavelength of 700 to 705 nm. IR700 undergoes a structural change while emitting fluorescence due to a photoreaction, and when it destroys tumor cells and plays a role as a drug, it stops emitting fluorescence. The treatment system 10 according to the present embodiment irradiates near-infrared light to the antibody-photosensitive substance accumulated in tumor cells, and detects a change in the fluorescence emitted by the antibody-photosensitive substance, thereby measuring in real time that the tumor cells are destroyed by the photoreaction of the antibody-photosensitive substance. Note that "real time" is not strictly limited to performing at almost the same time, but means a broad concept in which detection of a change in the intensity of fluorescence emitted by the antibody-photosensitive substance is performed in parallel with irradiation of near-infrared light with a certain time difference, or irradiation and detection are repeated at short intervals of several seconds or less. The time difference can be a time lag caused by communication, calculation, etc., or a set or calculated value. Note that the treatment system 10 does not necessarily have to measure in real time as long as it can measure during treatment that the tumor cells have been destroyed by the photoreaction of the antibody-photosensitive substance.

[0018] As shown in FIGS. 1 and 2, the treatment system 10 includes an optical device 20 that irradiates and detects light within the mammary duct B, a light source device 30 that supplies light to the optical device 20, an analysis device 40 that analyzes the detected light, and a display device 50 that displays the analysis results.

[0019] The light source device 30 has an output unit 31 that can output near-infrared light of an arbitrary wavelength with an arbitrary intensity (power) and energy, and a reference light output unit 32 that outputs the same light as the output unit 31 as reference light. The output unit 31 is connected to the optical device 20. The reference light output unit 32 is connected to the analysis device 40. The light source device 30 outputs light to the optical device 20 so that light with an energy of, for example, 1 to 50 J / cm can be irradiated from the optical device 20 at a wavelength of, for example, 660 to 740 nm. -2

[0020] The optical device 20 includes a shaft portion 21 inserted into the mammary duct B, an input cable 22 connected to the light source device 30, an output cable 23 connected to the analysis device 40, and an optical circulator 24.

[0021] The proximal end portion of the input cable 22 can be connected to the output unit 31 of the light source device 30, and the distal end portion of the input cable 22 is connected to the optical circulator 24. The input cable 22 has at least one optical fiber that propagates light, and propagates the light received from the output unit 31 to the optical circulator 24.

[0022] The proximal end portion of the output cable 23 can be connected to the analysis device 40, and the distal end portion of the output cable 23 is connected to the optical circulator 24. The output cable 23 has at least one optical fiber that propagates light, and propagates the light received from the optical circulator 24 to the analysis device 40.

[0023] ​The shaft portion 21 includes at least one optical fiber 27 that propagates light. The proximal end portion of the shaft portion 21 is connected to the optical circulator 24. The distal end portion of the shaft portion 21 includes an irradiation unit 25 that irradiates light to the outside and a detection unit 26 that detects external light. Each of the shaft portion 21, the input cable 22, and the output cable 23 may be composed of one fiber or a plurality of bundled fibers.

[0024] The optical circulator 24 propagates the light received from the input cable 22 to the shaft portion 21. Further, the optical circulator 24 propagates the light received from the shaft portion 21 to the output cable 23. Note that the optical device 20 may not include the optical circulator 24. For example, the shaft portion 21 may include a plurality of optical fibers 27, the optical fiber 27 connected to the irradiation unit 25 of the shaft portion 21 may be connected to the input cable 22, and the optical fiber 27 connected to the detection unit 26 of the shaft portion 21 may be connected to the output cable 23.

[0025] The irradiation unit 25 irradiates the outside with the light propagated from the proximal end side to the distal end side through the optical fiber 27. The irradiation unit 25 may be configured by, for example, a structure in which the cut end of the optical fiber 27 is exposed, a structure in which the surface coating is peeled off, a lens, a diffuser, or a mirror. The irradiation unit 25 is appropriately designed so that it can irradiate near-infrared light at a predetermined irradiation angle in a predetermined direction. Note that the structure of the irradiation unit 25 is not limited as long as it can irradiate light to the outside. Further, the irradiation direction of the irradiation unit 25 (the direction in which the center of the irradiation angle is located) is not particularly limited. For example, the irradiation direction of the irradiation unit 25 may be the distal end direction of the shaft portion 21 or a direction substantially orthogonal to the axis of the shaft portion 21.

[0026] The detection unit 26 receives external light into the interior of the optical fiber 27 and detects the light. The light that has entered the interior of the optical fiber 27 is propagated toward the proximal end side of the optical fiber 27. The detection unit 26 can be constituted by, for example, a structure in which the surface coating of the optical fiber 27 is peeled off, a lens, a diffuser, a mirror, or the like. The detection unit 26 may have the same structure as the irradiation unit 25. That is, the detection unit 26 may be the irradiation unit 25.

[0027] The analyzer 40 is a device that monitors during treatment that near-infrared light is acting on a tumor C having tumor cells. The monitoring is performed in real time, but it does not have to be performed in real time. The analyzer 40 includes a detection light input unit 41 that receives the light detected by the detection unit 26 of the optical device 20, and a reference light input unit 42 that receives reference light from the reference light output unit 32 of the light source device 30. The detection light input unit 41 is connected to the output cable 23 of the optical device 20. The reference light input unit 42 is connected to a reference light cable 33 that is connected to the reference light output unit 32 of the light source device 30.

[0028] The analyzer 40 can receive light from the output cable 23 of the optical device 20, analyze the intensity of light at each wavelength, and monitor that the tumor cells in which the antibody-photosensitive substance has accumulated are destroyed.

[0029] As a physical configuration of the hardware, the analyzer 40 includes a photoelectric conversion unit 43 that converts light into an electrical signal after passing through a filter that splits light into each wavelength or selectively extracts only a specific wavelength, a storage unit 44, and a processing unit 45. The storage unit 44 is, for example, a semiconductor memory element such as a RAM (Random Access Memory) or a flash memory, or a hard disk, an optical disk, or the like. The storage unit 44 can write or read, according to the processing situation, a fluorescence threshold value T and a program, which will be described later.

[0030] The processing unit 45 is, for example, a CPU (Central Processing Unit), an MPU (Micro Processing Unit), or the like. The processing unit 45 can execute the program stored in the storage unit 44 using, for example, the RAM as a work area to perform arithmetic processing. The processing unit 45 monitors the change in the intensity of the fluorescence FL of the wavelength emitted by the antibody-photosensitive substance that has received near-infrared light, and when the intensity of the fluorescence FL becomes equal to or less than the threshold value T or less than the threshold value T, as shown in FIGS. 1 and 3, it notifies the operator via the display device 50. Alternatively, when the intensity of the fluorescence FL becomes equal to or less than the threshold value T or less than the threshold value T, the processing unit 45 controls the light source device 30 via the connection cable 46 connected to the analyzer 40, and may stop or reduce the light output from the output unit 31 of the light source device 30. Further, the processing unit 45 calculates the intensity of the reference light RefL input to the reference light input unit 42. Furthermore, the processing unit 45 calculates the intensity of the reflected light RL of the same wavelength as the irradiation light (the same wavelength as the reference light RefL) and the intensity of the fluorescence FL having a wavelength different from the reference light RefL and the reflected light RL from the light input to the detection light input unit 41. The processing unit 45 transmits a signal representing the calculated result to the display device 50, and it can be displayed on the display panel 52 described later.

[0031] As shown in FIG. 1, the display device 50 is connected to the analyzer 40 by a display cable 51. The display device 50 can receive a display signal from the analyzer 40 via the display cable 51 and display information for notifying the operator on the display panel 52. The display device 50 may be provided with a sound output unit (speaker) for notifying the operator by sound.

[0032] Next, an example of a breast cancer treatment method using the treatment system 10 according to the first embodiment will be described with reference to the flowchart in the processing unit 45 shown in FIG. 5. Note that this description does not limit the structure of the treatment system 10.

[0033] First, the operator administers the antibody-photosensitive substance into a blood vessel, within lactiferous duct B, or within a lymphatic vessel. When the operator administers the antibody-photosensitive substance into a blood vessel, it is administered intravenously or into an artery. When the operator administers the antibody-photosensitive substance intravenously, after about 12 to 36 hours have elapsed since the administration, a known guide wire (not shown) is inserted into the lactiferous duct opening Bo that can reach the lactiferous duct B disposed near the tumor C shown in FIG. 2. Next, the proximal end of the guide wire is inserted into the lumen of the catheter 60 (for example, a microcatheter), and the catheter 60 is inserted into the lactiferous duct B from the lactiferous duct opening Bo along the guide wire. After this, the operator removes the guide wire from the catheter 60. In addition, when the operator locally administers the antibody-photosensitive substance into the artery that nourishes the tumor cells, the operator waits until the antibody-photosensitive substance accumulates on the target cell membrane. When the antibody-photosensitive substance is locally administered to the nutrient artery of the organ in which the tumor C to be treated is present, the time until the antibody-photosensitive substance accumulates on the target cell membrane is considered to be shorter than in the case of intravenous administration, for example, about 5 to 10 minutes.

[0034] Next, the operator inserts the shaft portion 21 of the optical device 20 into the catheter 60 from the proximal end side of the catheter 60. The distal end portion of the optical device 20 protrudes from the catheter 60 to the distal end side. Next, the operator causes the distal end portion of the optical device 20 to reach the target position while confirming it, for example, under ultrasonic fluoroscopy. The target position is a position close to the tumor C and capable of irradiating the tumor C with near-infrared light. When the target position is close to the body surface, the surroundings may be darkened, and the position of the distal end portion may be directly visually recognized from the body surface by outputting landmark light from the distal end of the optical device 20, or it may be detected and confirmed with a high-sensitivity camera.

[0035] Next, the operator checks the treatment preparation, treatment position, setting of the threshold value T, etc. For this purpose, the operator operates the analyzer 40 that controls the light source device 30 to output near-infrared light from the light source device 30 (step S10). The light source device 30 outputs near-infrared light with a wavelength of, for example, 689 nm at a predetermined intensity (power) from the output unit 31 and the reference light output unit 32. The reference light RefL output from the reference light output unit 32 is input to the reference light input unit 42 of the analyzer 40. Further, the near-infrared light output from the output unit 31 of the light source device 30 passes through the input cable 22, the optical circulator 24, and the shaft portion 21, and is irradiated from the irradiation unit 25 disposed at the tip of the shaft portion 21 toward the tumor C. The detection unit 26 disposed at the tip of the shaft portion 21 detects external light. The detection unit 26 detects the reflected light RL having the same wavelength as the near-infrared light (irradiation light) irradiated from the irradiation unit 25, and the fluorescence FL (700 to 705 nm) having a wavelength different from that of the irradiation light (or the reflected light RL) emitted by the antibody-photosensitive substance excited by receiving the near-infrared light. The light detected by the detection unit 26 passes through the shaft portion 21, the optical circulator 24, and the output cable 23 and is input to the detection light input unit 41 of the analyzer 40. The processing unit 45 of the analyzer 40 receives the signals of the reference light RefL, the reflected light RL, and the fluorescence FL (step S11).

[0036] The processing unit 45 of the analysis device 40 calculates in real time the intensity of the reference light RefL received by the reference light input unit 42 and the intensities of the reflected light RL and the fluorescence FL received by the detection light input unit 41 (step S12). Next, as shown in FIG. 3, the processing unit 45 causes the calculated intensities of the reference light RefL, the reflected light RL, and the fluorescence FL to be displayed on the display panel 52 of the display device 50 in real time (step S13). The operator moves the position of the irradiation unit 25 while looking at the display panel 52 to measure the intensity and distribution of the fluorescence FL. When the operator sets the threshold value T or changes the threshold value T from the measured results, the operator can operate the analysis device 40 to input the threshold value T (step S14). The processing unit 45 of the analysis device 40 sets the input value as the threshold value T (step S15). The threshold value T may be a predetermined absolute value to be set, or a ratio of the intensity of the fluorescence FL to the intensity of the reference light RefL, or a ratio of the detected intensity of the fluorescence FL to the intensity of the reflected light RL. The threshold value T may be preset instead of being input by the operator during the procedure.

[0037] After measuring the intensity and distribution of the fluorescence FL, the operator determines the treatment procedure for the tumor C (for example, division into a plurality of treatment sites or the threshold value T). Next, the operator holds the irradiation unit 25 at a position where near-infrared light can be irradiated to the site where the treatment of the tumor C is to be performed first, and operates the analysis device 40 to start the treatment (step S16). When the operator starts the treatment, the processing unit 45 starts measuring the irradiation time (step S17).

[0038] When the antibody-photosensitive substance accumulated in the tumor cells is irradiated with near-infrared light, the antibody-photosensitive substance undergoes a photoreaction to emit fluorescence FL and destroys the tumor cells. Note that the antibody-photosensitive substance does not emit fluorescence FL after destroying the tumor cells. Therefore, by measuring in real time the change in the intensity of the detected fluorescence FL, the progress state of the photoreaction that destroys the tumor cells can be confirmed.

[0039] As described above, the processing unit 45 of the analysis device 40 causes the display panel 52 of the display device 50 to display the calculated intensities of the reference light RefL, the reflected light RL, and the fluorescence FL in real time (step S13). Note that the ratio of the reflected light RL to the reference light RefL is substantially constant. Therefore, only one of the reference light RefL or the reflected light RL may be measured. The processing unit 45 determines whether the intensity of the detected fluorescence FL is less than (or less than or equal to) the set threshold value T (step S18). If the processing unit 45 determines that the intensity of the fluorescence FL is not less than (or less than or equal to) the threshold value T, it continues the output of the near-infrared light from the light source device 30, considering that the progress of the photoreaction for destroying the tumor cells is insufficient, and returns to step S11. If the processing unit 45 determines that the intensity of the fluorescence FL is less than (or less than or equal to) the threshold value T, it determines that the photoreaction for destroying the tumor cells has been sufficiently performed. Next, the processing unit 45 outputs a threshold arrival signal indicating that the intensity of the fluorescence FL has become less than (or less than or equal to) the threshold value T, transmits the threshold arrival signal to the display device 40, and causes it to be displayed on the display panel 52 in real time (step S19).

[0040] Note that the reason why the intensity of the fluorescence FL becomes less than (or less than or equal to) the threshold value T may be that sufficient irradiation has been performed and the photoreaction has progressed, or that a foreign substance such as body fluid has invaded the irradiation site and the fluorescence RL cannot be detected. Therefore, the operator or the processing unit 45 may start the irradiation of the near-infrared light from the light source device 30 after confirming that the irradiation light RefL, the reflected light RL, and the fluorescence FL have a certain relationship. During the irradiation of the near-infrared light, if the fluorescence FL decreases without the relationship between the reference light RefL and the reflected light RL changing, the processing unit 45 determines that the irradiation of the near-infrared light and the photoreaction are proceeding stably. Also, during the irradiation of the near-infrared light, if the reflected light RL with respect to the reference light RefL, or the reflected light RL and the fluorescence FL decrease significantly, the processing unit 45 determines that the irradiation state has changed due to a foreign substance. The processing unit 45 can transmit the determined result to the display device 40 and cause it to be displayed on the display panel 52. In this way, the detection result of the reflected light RL may be used to determine whether stable irradiation of the near-infrared light for the photoreaction is being performed.

[0041] Next, the processing unit 45 determines whether the irradiation time since the output of the near-infrared ray started has become equal to or exceeded a preset minimum irradiation time (step S20). The minimum irradiation time is the minimum irradiation time set to ensure a minimum irradiation amount. Therefore, after starting the output of the near-infrared ray from the light source device 30, the processing unit 45 does not stop the irradiation until the irradiation time becomes equal to or exceeds the minimum irradiation time.

[0042] If the processing unit 45 determines that the irradiation time has not become equal to or exceeded the minimum irradiation time, it continues the output of the near-infrared ray from the light source device 30 and returns to step S02. Then, if the processing unit 45 determines that the irradiation time has become equal to or exceeded the minimum irradiation time, it causes the display device 50 to display in real time information indicating that the condition for completing the treatment (near-infrared ray irradiation) of the treatment site has been satisfied (step S21). Thereby, the treatment of the treatment site selected at first is completed.

[0043] Note that the minimum irradiation time may not be set. In this case, in step S18, if the processing unit 45 determines that the intensity of the fluorescence FL is less than the threshold value T (or less than or equal to the threshold value T), it does not perform steps S15 to S16 and causes the display device 50 to display in real time information indicating that the condition for stopping the output of the near-infrared ray has been satisfied (step S21). In step S21, there may be a function of displaying that the condition for stopping the output is satisfied and temporarily stopping the output. When temporarily stopping the output, the light source is stopped or at least a part of the optical path including the input cable 22 is shielded from light.

[0044] Next, when the operator finishes treating the selected treatment site, the operator can operate the analyzer 40 to select whether to treat other parts of the tumor C or to end the treatment of the tumor C (step S22). The operator shifts, moves, and holds the irradiation unit 25 to a position where near-infrared light can be irradiated to the next treatment site. After that, the operator starts treating the new treatment site (step S16). Then, the operator measures the change in the intensity of the fluorescence FL in real time as described above, and performs treatment with near-infrared light until the conditions for completing the treatment are satisfied (step S21). Thereby, the operator can sequentially treat a plurality of treatment sites. When the operator treats all the treatment sites of the tumor C and determines that there are no other treatment sites, the operator operates the analyzer 40 to select whether to end the treatment of the tumor C (step S22). Thereby, the processing unit 45 stops the output of the near-infrared light from the light source device 30 (step S23). In this way, the operator can alternately repeat the movement of the position of the irradiation unit 25 and the treatment of destroying tumor cells by photoreaction, and destroy tumor cells distributed over a wide range. Finally, the operator removes the optical device 20 and the catheter 60 from the mammary duct B to complete the procedure. Note that the processing unit 45 may stop the irradiation of the near-infrared light every time the treatment of each selected treatment site is completed, and may start the irradiation of the near-infrared light every time the treatment of each selected treatment site is started.

[0045] Note that if the optical device 20 has a certain degree of rigidity and can be pushed into the mammary duct B alone, the catheter 60 and the guide wire may not be used when inserting the optical device 20 into the mammary duct B. For example, the tip of the optical device 20 may be curved and shaped so as to be directed in any direction within the mammary duct B. Alternatively, a wire-shaped protrusion may be formed to protrude from the tip of the optical device 20 so that the direction in the mammary duct B can be easily set.

[0046] Also, as shown in FIG. 4, when performing treatment, the operator may deform the breast by sandwiching it so as to bring the irradiation unit 25 and / or the detection unit 26 closer to the tumor C. The direction in which the breast is sandwiched can be determined based on the measurement results of the intensity and distribution of the overall fluorescence FL of the tumor C performed before the treatment.

[0047] As described above, the treatment system 10 according to the first embodiment is a treatment system 10 that irradiates excitation light to an antibody-photosensitive substance accumulated in tumor cells in breast cancer tumor cells, and includes an optical fiber 27 capable of propagating light between a proximal end portion and a distal end portion, and has an optical device 20 provided with an irradiation unit 25 capable of irradiating light to the outside at the distal end portion and a detection unit 26 capable of detecting external light, and the distal end portion of the optical device 20 can be inserted from the lactiferous duct opening Bo into the lactiferous duct B.

[0048] The treatment system 10 configured as described above arranges the irradiation unit 25 and the detection unit 26 of the optical device 20 at positions close to the tumor cells in the lactiferous duct B, so that near-infrared light can be effectively irradiated to the antibody-photosensitive substance accumulated in the tumor cells, and the fluorescence FL emitted by the antibody-photosensitive substance accumulated in the tumor cells can be effectively detected. Therefore, the treatment system 10 can perform treatment while confirming the degree of destruction of tumor cells by irradiation with near-infrared light by detecting the fluorescence FL, and can improve the treatment effect.

[0049] In addition, the treatment system 10 has an analyzer 40 connected to the proximal end portion of the optical device 20 and receiving and analyzing the light detected by the detection unit 26. The analyzer 40 calculates the intensity of the fluorescence FL received from the detection unit 26, and when the intensity of the fluorescence FL becomes equal to or less than a threshold value T or less than the threshold value T, outputs a threshold value arrival signal indicating that it has become equal to or less than the threshold value T or less than the threshold value T. Thereby, the treatment system 10 can notify the operator that the intensity of the fluorescence FL has become equal to or less than the threshold value T or less than the threshold value T, or can stop the irradiation of the excitation light.

[0050] In addition, the treatment method in this embodiment is a treatment method of irradiating excitation light to an antibody-photosensitive substance accumulated in breast cancer tumor cells, and includes steps of administering the antibody-photosensitive substance into a blood vessel, within the breast duct B, or within a lymphatic vessel; inserting a light device 20 having an optical fiber 27 from a breast duct opening Bo into the breast duct B; irradiating excitation light toward the antibody-photosensitive substance accumulated in the tumor cells; and detecting fluorescence FL emitted by the antibody-photosensitive substance irradiated with the excitation light, and the irradiating step and / or the detecting step are performed by the light device 20 inserted into the breast duct B.

[0051] The treatment method configured as described above can effectively perform irradiation of excitation light to the antibody-photosensitive substance accumulated in breast cancer tumor cells and / or detection of fluorescence FL by the light device 20 inserted near the tumor cells. Therefore, this treatment method can perform treatment while confirming in real time the degree of destruction of tumor cells by irradiation of excitation light by detecting fluorescence FL, and can improve the treatment effect.

[0052] In addition, the excitation light is near-infrared light, the light device 20 has an irradiation unit 25 capable of irradiating near-infrared light and a detection unit 26 capable of detecting external light, the step of irradiating the excitation light is performed by the irradiation unit 25, and the step of detecting the fluorescence emitted by the antibody-photosensitive substance may be performed by the detection unit 26. Thereby, this treatment method can perform treatment while confirming the degree of destruction of tumor cells by irradiation of near-infrared light, and can improve the treatment effect.

[0053] In addition, the treatment method includes a step of comparing the intensity of the fluorescence FL detected by the detection unit 26 with a threshold value T, and a step of changing the position of the irradiation unit 25 capable of irradiating near-infrared light or stopping the irradiation of near-infrared light when the intensity of the fluorescence FL reaches or exceeds the threshold value T. Thereby, this treatment method can perform treatment while accurately confirming the degree of destruction of tumor cells by irradiation of near-infrared light by comparing the intensity of the fluorescence FL with the threshold value T. Therefore, this treatment method can further improve the treatment effect.

[0054] Further, before the step of irradiating the excitation light, the treatment method includes a step of detecting the fluorescence FL emitted by the antibody-photosensitive substance irradiated with near-infrared light while changing the position of the irradiation unit 25, and confirming the position where the fluorescence FL is emitted and the intensity of the fluorescence FL. As a result, after accurately grasping the distribution of breast cancer tumor cells, this treatment method can effectively destroy the tumor cells as much as possible without leaving any tumor cells behind.

[0055] Further, in the step of irradiating the excitation light and the step of detecting the fluorescence FL, the treatment method may deform the breast to be thinner and bring the positions of the irradiation unit 25 and / or the detection unit 26 closer to the tumor cells where the antibody-photosensitive substance has accumulated. As a result, the irradiation of the excitation light from the irradiation unit 25 to the antibody-photosensitive substance and / or the detection of the fluorescence FL emitted by the antibody-photosensitive substance can be effectively performed.

[0056] <Second Embodiment> As shown in FIGS. 6 and 7, the treatment system 10 according to the second embodiment is different from the first embodiment in that the distal end portion of the shaft portion 21 of the optical device 20 has an expandable portion 70 that can expand in the radial direction and has a sheath 71 that can contract and accommodate the expandable portion 70.

[0057] The shaft portion 21 has an expandable portion 70 connected to its distal end portion that can expand and contract in the radial direction (a direction perpendicular to the axis of the shaft portion 21). The expandable portion 70 is formed in a mesh shape by a light-conducting body capable of propagating light. The proximal end portion of the expandable portion 70 is connected to the shaft portion 21, and the distal end portion of the expandable portion 70 spreads out to have an outer diameter larger than the outer diameter of the shaft portion 21 in a natural state where no external force acts. That is, in the natural state, the expandable portion 70 is formed in a cylindrical shape such that the inner diameter and the outer diameter expand toward the distal end side while having gaps due to being in a mesh shape. The expandable portion 70 is woven with a plurality of thin wire materials 72 having gaps, and at the distal end portion of the expandable portion 70, the plurality of wire materials 72 are connected so as not to come loose.

[0058] The expansion part 70 preferably has a structure that applies radial force to the inner wall of the milk duct B as little as possible during expansion. Thereby, the burden on the milk duct B due to the expansion of the expansion part 70 can be reduced. For this purpose, the material forming the expansion part 70 is formed of, for example, a highly elastic rubber material or a thin and flexible filamentous member.

[0059] At least one of the plurality of wire rods 72 forming the expansion part 70 may be an optical fiber 27 that extends from the shaft part 21 and is supplied with near-infrared light. The optical fiber 27 forming at least a part of the expansion part 70 is provided with at least one of the irradiation part 25 and the detection part 26 in the axial direction of the optical fiber 27. The optical fiber 27 forming at least a part of the expansion part 70 may have a plurality of irradiation parts 25 arranged in the axial direction of the optical fiber 27 or an irradiation part 25 formed long in the axial direction. Further, the optical fiber 27 forming at least a part of the expansion part 70 may have a plurality of detection parts 26 arranged in the axial direction of the optical fiber 27 or a detection part 26 formed long in the axial direction. Further, at the base end part of the optical device 20 (for example, the base end part of the shaft part 21), a position marker 73 is arranged so as to coincide with the circumferential positions of the irradiation part 25 and the detection part 26 of the expansion part 70. The position marker 73 is used for the operator to grasp the circumferential positions of the irradiation part 25 and the detection part 26 that are inserted into the milk duct B and not visible to the operator.

[0060] The sheath 71 is a cylindrical member capable of accommodating the shaft part 21 and the expansion part 70. As shown in Fig. 6(A), the sheath 71 moves in the distal direction with respect to the shaft part 21 and the expansion part 70 to radially contract and accommodate the expansion part 70. The sheath 71 moves in the proximal direction with respect to the shaft part 21 and the expansion part 70 from the state of accommodating the expansion part 70 to release the expansion part 70 as shown in Fig. 6(B). Thereby, the expansion part 70 restores to its original expanded shape by its own elastic force.

[0061] When using the treatment system 10 according to the second embodiment, as shown in Fig. 6(A), the operator inserts the optical device 20 into the lactiferous duct B from the lactiferous duct opening Bo with the expansion part 70 accommodated in the sheath 71. After that, as shown in Figs. 6(B) and 7, the operator moves the sheath 71 in the proximal direction to release the expansion part 70 from the sheath 71.

[0062] Thereby, the expansion part 70 expands by its own restoring force, contacts the inner wall of the lactiferous duct B, or is disposed near the inner wall of the lactiferous duct B. The irradiation part 25 and the detection part 26 are disposed on the expansion part 70. Therefore, since near-infrared light can be irradiated near the inner wall of the lactiferous duct B, it is possible to suppress the influence of the body fluid in the lactiferous duct B that obstructs the light from affecting the light irradiation. For this reason, near-infrared light can be effectively irradiated onto the antibody-photosensitive substance accumulated in the tumor cells. Also, since light can be detected near the inner wall of the lactiferous duct B, it is possible to suppress the influence of the body fluid in the lactiferous duct B that obstructs the light from affecting the light detection. For this reason, the detection part 26 can effectively detect the reflected light RL of the near-infrared light and the fluorescence FL emitted by the antibody-photosensitive substance. The body fluid in the lactiferous duct B can flow through the gaps of the mesh-like expansion part 70. For this reason, the expansion part 70 is likely to expand without being obstructed by the body fluid and contact the inner wall of the lactiferous duct B or be located near the inner wall of the lactiferous duct B.

[0063] Also, the operator can direct the circumferential positions of the irradiation part 25 and the detection part 26 in a desired direction by confirming the position of the position marker 73 at the proximal end of the optical device 20.

[0064] As described above, the treatment system 10 according to the second embodiment has an expansion part 70 at the distal end of the optical device 20 that can expand and contract in the radial direction, and the irradiation part 25 and the detection part 26 are disposed on the expansion part 70. Thereby, by expanding the expansion part 70 in the lactiferous duct B, the irradiation part 25 and the detection part 26 can be disposed near the inner wall of the lactiferous duct B. For this reason, the influence of the body fluid in the lactiferous duct B that obstructs the light is reduced, and near-infrared light can be effectively irradiated from the irradiation part 25 onto the antibody-photosensitive substance accumulated in the tumor cells, and the fluorescence FL emitted by the antibody-photosensitive substance can be effectively detected.

[0065] In addition, the treatment method in the second embodiment includes a step of expanding the tip of the optical device 20 inserted into the mammary duct B and disposing the irradiation unit 25 and / or the detection unit 26 in the vicinity of the inner wall of the mammary duct B. Thereby, the influence of the body fluid in the mammary duct B that obstructs the transmission of light can be reduced, and the irradiation of near-infrared light from the irradiation unit 25 to the antibody-photosensitive substance and / or the detection of the fluorescence FL emitted by the antibody-photosensitive substance can be effectively performed.

[0066] Note that the structure of the expansion part 70 is not particularly limited. For example, the expansion part 70 may be a so-called self-expandable stent-like member in which a plurality of slit-shaped through-holes penetrating from the outer peripheral surface to the inner peripheral surface are formed in a circular tube as a material, and the tip part is shaped in a state where the diameter is expanded outward in the radial direction. In this case, the optical fiber 27 having the irradiation unit 25 and the detection unit 26 is fixed so as to be wound around the expansion part 70. Further, the expansion part 70 may be formed of a light guide other than an optical fiber, and has a structure capable of receiving near-infrared light from the optical fiber 27 forming the shaft part 21 and irradiating it to the outside, and receiving light from the outside and propagating the light to the optical fiber 27.

[0067] In addition, the expansion part 70 may include an outer tube 73 that houses the shaft part 21 including the optical fiber 27 as shown in the modified example of FIG. 8. The tip part of the expansion part 70 including the plurality of wire rods 72 is fixed to the tip part of the shaft part 21, and the base end part of the expansion part 70 is fixed to the tip part of the outer tube 73. The expansion part 70 is a light guide connected to the optical fiber 27 forming the shaft part 21 or a part of the optical fiber 27. As shown in FIG. 8(B), the operator can apply an axial compressive force to the expansion part 70 by moving the outer tube 73 in the tip direction with respect to the shaft part 21. Thereby, the expansion part 70 can expand outward in the radial direction. Further, as shown in FIG. 8(A), the operator can contract the expansion part 70 inward in the radial direction by moving the outer tube 73 in the base end direction with respect to the shaft part 21.

[0068] Alternatively, the extension portion may be a wire wound in one or more spiral (coil) shapes, a balloon that expands by allowing a fluid to flow in, or the like.

[0069] <Third Embodiment> The treatment system 10 according to the third embodiment is different from the first embodiment in that it separately includes a first optical device 80 having an irradiation unit 25 and a second optical device 90 having a detection unit 26, as shown in FIG. 9.

[0070] The first optical device 80 has a first shaft portion 81 provided with an optical fiber 27 that receives near-infrared light from the output portion 31 of the light source device 30, and an irradiation unit 25 that irradiates near-infrared light is disposed at the tip of the first shaft portion 81. The second optical device 90 has a second shaft portion 91 provided with an optical fiber 27 that propagates light to the detection light input portion 41 of the analysis device 40, and a detection unit 26 that detects external reflected light RL and fluorescence FL is provided at the tip of the second shaft portion 91.

[0071] When using the treatment system 10 according to the third embodiment, the operator inserts the first shaft portion 81 from the lactiferous duct opening Bo into the lactiferous duct B, and arranges the irradiation unit 25 at a position where near-infrared light can be irradiated onto the antibody-photosensitive substance accumulated in the tumor cells. After that, the operator inserts the second shaft portion 91 from the lactiferous duct opening Bo and inserts it into a lactiferous duct B different from the lactiferous duct B where the irradiation unit 25 is arranged. Next, the operator arranges the detection unit 26 at a position where fluorescence FL from the tumor cells irradiated with near-infrared light can be detected. After that, the operator operates the analysis device 40 that controls the light source device 30 to irradiate near-infrared light from the irradiation unit 25, and the reflected light RL and fluorescence FL are detected by the detection unit 26. Thereby, the operator can measure the change in the intensity of the detected fluorescence FL in real time and confirm the progress state of the photoreaction that destroys the tumor cells.

[0072] In addition, as another modification in which the first optical device 80 and the second optical device 90 are different, the first optical device 80 including the irradiation unit 25 may be inserted into the milk duct B, and the second optical device 90 including the detection unit 26 may be disposed on the skin of the breast or the like outside the body. Further, as still another example, the second optical device 90 including the detection unit 26 may be inserted into the milk duct B, and the first optical device 80 including the irradiation unit 25 may be disposed on the skin of the breast or the like outside the body.

[0073] <Fourth Embodiment> As shown in FIG. 10, the optical device 100 of the treatment system 10 according to the fourth embodiment may be an OCT catheter that detects reflected light and forms a tomographic image of biological tissue by optical coherence tomography (OCT). The optical device 100 includes a long outer tube 101, a scanning unit 102 that is disposed within the outer tube 101 and serves as both an irradiation unit that irradiates light and a detection unit that detects light, a drive shaft 103 that is disposed within the outer tube 101 and rotationally drives the scanning unit 102, a drive source 104 that applies a rotational force to the drive shaft 103, an optical fiber 105 that is disposed inside the drive shaft 103 and rotates together with the drive shaft 103 and is connected to the scanning unit 102, and a control unit 106 that is connected to the optical fiber 105 and creates a tomographic image. The control unit 106 includes a light source device and an analysis device. The control unit 106 controls the drive source 104 to rotate the drive shaft 103 and the scanning unit 102. Then, the control unit 106 causes the scanning unit 102 to irradiate light and detect the reflected light, and can create a full-perimeter tomographic image surrounding the optical device 100. Thereby, the operator can grasp the position and distribution of the tumor C based on the tomographic image obtained from the OCT catheter 60. Then, the operator causes the control unit 106 to output near-infrared light from the scanning unit 102, which is the irradiation unit, and detect the reflected light RL and the fluorescence FL from the scanning unit 102, which is the detection unit. Thereby, the operator can measure in real time the destruction of tumor cells by the photoreaction of the antibody-photosensitive substance using the OCT catheter that forms the tomographic image. At this time, since the scanning unit 102, which is both the irradiation unit and the detection unit, rotates, it can output near-infrared light all around so as to surround the optical device 100 and detect light all around. Therefore, the optical device 100 can effectively destroy a wide range of tumor cells. Note that the scanning unit 102 does not necessarily have to rotate. Further, the scanning unit 102 may be able to obtain a three-dimensional image over a wide range in the axial direction by moving in the axial direction while rotating inside the outer tube 101, and may be able to destroy a wide range of tumor cells.

[0074] It is preferable that the outer tube 101 be in close contact with the milk duct B so that near-infrared light can be effectively irradiated from the scanning unit 102 to the antibody-photosensitive substance accumulated in the tumor cells, and the fluorescence FL emitted by the antibody-photosensitive substance can be effectively detected by the scanning unit 102. For this purpose, the outer diameter of the outer tube 101 is preferably slightly thicker than the inner diameter of the milk duct B, or it is preferable that the speculum be inserted into the milk duct B in advance before the outer tube 101 is inserted.

[0075] In addition, as a catheter for obtaining a tomographic image of a tissue including the tumor C, an ultrasonic (IVUS) catheter instead of an OCT catheter may be inserted into the milk duct B. The ultrasonic catheter can obtain a tomographic image to a deeper position than the OCT catheter. Since the ultrasonic catheter does not irradiate light for detection, it is used in combination with the optical device 20 of the treatment system 10 according to the first to third embodiments. When using ultrasonic waves, since measurement cannot be performed if air is present between the ultrasonic oscillator and the observation target, it is preferable that the ultrasonic catheter be in close contact with the inner wall of the milk duct B. For this purpose, for example, a thick speculum or a balloon filled with a liquid may be disposed on the surface of the ultrasonic catheter.

[0076] As described above, the treatment method in the fourth embodiment includes a step of inserting a catheter for obtaining a tomographic image from the milk duct opening Bo into the milk duct before the step of irradiating near-infrared light, and obtaining a tomographic image of a tissue including tumor cells in which the antibody-photosensitive substance has accumulated. Thereby, after accurately grasping the distribution of the tumor cells of breast cancer, this treatment method can effectively destroy the tumor cells as much as possible without leaving them.

[0077] Note that the present invention is not limited only to the above-described embodiments, and various modifications can be made by those skilled in the art within the technical idea of the present invention.

[0078] For example, as another example of the treatment method, a fluorescent reagent (e.g., ICG (indocyanine green)) having an excitation wavelength different from that of the target antibody-photosensitive substance may also be administered in advance into blood vessels, within lactiferous duct B, or within lymphatic vessels. The timing and location of administering the fluorescent reagent may be the same as or different from those of the antibody-photosensitive substance. As a result, not only the antibody-photosensitive substance but also the fluorescent reagent accumulates in tumor cells. Indocyanine green is excited by light with a wavelength of, for example, 774 nm and emits fluorescence FL2 with a wavelength of 805 nm. Therefore, light including near-infrared light with a wavelength (e.g., 689 nm) that excites the antibody-photosensitive substance and light with a wavelength (e.g., 774 nm) that excites the fluorescent reagent different from the antibody-photosensitive substance is irradiated from the irradiation unit 25. Thereby, as shown in FIG. 11, the processing unit 45 can calculate the intensities of the reference light RefL (e.g., wavelength 689 nm), the reflected light RL (e.g., wavelength 689 nm) with the same wavelength as the near-infrared light irradiated from the irradiation unit 25, the fluorescence FL (e.g., wavelength 704 nm) emitted by the antibody-photosensitive substance accumulated in tumor cells, and the fluorescence FL2 (e.g., wavelength 805 nm) emitted by the fluorescent reagent accumulated in tumor cells, and display them on the display device 50. Note that when the antibody-photosensitive substance undergoes a photoreaction upon receiving near-infrared light and destroys tumor cells, it stops emitting fluorescence FL. Therefore, it becomes difficult to identify the site where tumor cells were present based on fluorescence FL. In contrast, even when the antibody-photosensitive substance undergoes a photoreaction, the fluorescent reagent does not undergo a chemical change, so it can emit fluorescence FL2.

[0079] Also, as another different example of the treatment device and the treatment method, photodynamic therapy (PDT) may be performed by pre-administering only a photosensitive substance represented by 5-aminolevulinic acid (ALA), Photofrin (Porfimer sodium), or verteporfin and irradiating the tumor cells with excitation light.

[0080] As described above, the treatment method may include administering, into a blood vessel, a lactiferous duct B, or a lymphatic vessel, a fluorescent reagent that has an excitation wavelength different from that of the antibody-photosensitive substance and is capable of emitting fluorescence FL2 having a wavelength different from that of the fluorescence FL emitted by the antibody-photosensitive substance; irradiating the tumor cells with light having the excitation wavelength of the fluorescent reagent; and detecting the fluorescence FL2 emitted by the fluorescent reagent accumulated in the tumor cells. Even if the antibody-photosensitive substance undergoes a photoreaction and stops emitting fluorescence FL, the operator can easily recognize the progress of tumor cell destruction caused by the photoreaction of the antibody-photosensitive substance based on the fluorescence FL2 emitted by the fluorescent reagent.

[0081] This application is based on Japanese Patent Application No. 2020-059473 filed on Mar. 30, 2020, the disclosure of which is incorporated herein by reference in its entirety.

Explanation of Reference Numerals

[0082] 10 Treatment system 20, 100 Light device 25 Irradiation unit 26 Detection unit 27 Optical fiber 30 Light source device 40 Analyzer 50 Display device 70 Extension unit 80 First light device (light device) 81 First shaft portion 90 Second light device (light device) 91 Second shaft portion 102 Scanning unit (irradiation unit, detection unit) 105 Optical fiber 106 Control unit (light source device, analyzer) B Lactiferous duct Bo Lactiferous duct opening C Tumor FL Fluorescence emitted by the antibody-photosensitive substance FL2 Fluorescence emitted by the fluorescent reagent RefL Reference light RL Reflected light

Claims

1. A treatment system for irradiating an excitation light to a photosensitive substance accumulated in tumor cells, comprising: an optical device including an optical fiber capable of propagating light between a proximal end portion and a distal end portion, an irradiation unit capable of irradiating light to the outside at the distal end portion, and a detection unit capable of detecting external light; an analysis device connected to the proximal end portion of the optical device for receiving and analyzing the light detected by the detection unit; and the analysis device calculates the intensity of fluorescence received from the detection unit, and outputs a threshold arrival signal indicating that the intensity of the fluorescence has become equal to or less than a threshold value when the intensity of the fluorescence becomes equal to or less than the threshold value. A treatment system characterized by that.

2. The distal end portion of the optical device has an expansion portion that can expand and contract in the radial direction, The treatment system according to claim 1, wherein the irradiation unit and the detection unit are arranged in the expansion portion.

3. The treatment system according to claim 1 or 2, wherein the photosensitive substance is an antibody-photosensitive substance bound to an antibody that accumulates in tumor cells.

4. A treatment system for irradiating an excitation light to a photosensitive substance accumulated in tumor cells, comprising: an optical device including an optical fiber capable of propagating light between a proximal end portion and a distal end portion, an irradiation unit capable of irradiating light to the outside at the distal end portion, and a detection unit capable of detecting external light; an analysis device connected to the proximal end portion of the optical device for receiving and analyzing the light detected by the detection unit; and the analysis device calculates the intensity of fluorescence received from the detection unit in real time, and displays the calculated intensity of fluorescence on a display panel of a display device in real time. A treatment system characterized by that.

Images